[1]赵航,宋晓磊,郑璇,等.不同肝背景下大鼠移植性肝癌肿瘤生长及TACE治疗疗效的差异[J].介入放射学杂志,2024,33(10):1095-1100.
　ZHAO Hang,SONG Xiaolei,ZHENG Xuan,et al.The differences in the growth of transplanted hepatocellular carcinoma and the efficacy of TACE in experimental rats with different liver backgrounds[J].journal interventional radiology,2024,33(10):1095-1100.
点击复制

不同肝背景下大鼠移植性肝癌肿瘤生长及TACE治疗疗效的差异()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年10
页码:
1095-1100
栏目:
实验研究
出版日期:
2024-10-21

文章信息/Info

Title:
The differences in the growth of transplanted hepatocellular carcinoma and the efficacy of TACE in experimental rats with different liver backgrounds
作者:
赵航; 宋晓磊; 郑璇; 张煜杰; 周军
Author(s):
ZHAO Hang; SONG Xiaolei; ZHENG Xuan; ZHANG Yujie; ZHOU Jun.
Department of Intervention，Qilu Hospital （Qingdao） of Shandong University，Qingdao，Shandong Province 266000，China
关键词:
【关键词】肝动脉化疗栓塞; 肝癌; 脂肪肝; 肝硬化; 疗效差异; CD34
文献标志码:
A
摘要:
【摘要】目的探索正常肝、脂肪肝、肝硬化背景下大鼠移植性肝癌肿瘤生长时各项指标的差异以及TACE治疗后疗效的不同。方法将Walker-256腹水瘤细胞种植到正常肝、脂肪肝、肝硬化模型大鼠的肝脏内，并对其行TACE治疗。观察3组不同肝背景大鼠肿瘤生长时及TACE治疗后各项指标的差异。结果3组不同肝背景肿瘤体积间存在差异，但差异无统计学意义（P＞0.05）；治疗前肝功能未见明显差异，治疗后部分肝功能指标脂肪组明显高于硬化组，差异具有统计学意义（P＜0.05）；3组微血管密度未见明显差异（P＞0.05），但在同一组内，治疗前后对比3组皆有明显差异（P＜0.05）。结论肿瘤生长过程中：①肿瘤体积存在差异，肝硬化在前期会抑制肿瘤生长，但后期肝硬化大鼠的恶病质状态会加速肿瘤生长；②肝硬化组和脂肪肝组肝功能相似；③微血管密度未见明显差异，但随着肿瘤的增长微血管密度会稍增加。TACE治疗后：①肿瘤体积未见明显差异；②脂肪肝大鼠相对于肝硬化大鼠有较多的肝功能储备；③微血管密度未见明显差异，但栓塞治疗会刺激微血管的增生。

参考文献/References:

［1］Vogel A，Meyer T，Sapisochin G，et al.Hepatocellular carcinoma［J］.Lancet，2022，400：1345-1362.
［2］Liu Z，Xu K，Jiang Y，et al.Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030：a modelling study［J］.Int J Epidemiol，2021，50：128-142.
［3］Cai XJ，Zheng Q，Jiang GY.Current status and prospect of surgical treatment of liver cancer［J］.Zhonghua Wai Ke Za Zhi，2019，57：494-499.
［4］宗静静，卿鑫，樊哲，等.原发性肝癌治疗进展［J］.东南大学学报（医学版），2021，40：542-547.
［5］Blum HE.Hepatocellular carcinoma：therapy and prevention［J］.World J Gastroenterol，2005，11：7391-7400.
［6］Calle EE，Rodriguez C，Walker-Thurmond K，et al.Overweight，obesity，and mortality from cancer in a prospectively studied cohort of U.S.adults［J］.N Engl J Med，2003，348：1625-1638.
［7］Foerster F，Gairing SJ，Müller L，et al.NAFLD-driven HCC：safety and efficacy of current and emerging treatment options［J］.J Hepatol，2022，76：446-457.
［8］Chalasani N，Younossi Z，Lavine JE，et al.The diagnosis and management of nonalcoholic fatty liver disease：practice guidance from the American Association for the Study of Liver Diseases［J］.Hepatology，2018，67：328-357.
［9］Huang DQ，El-Serag HB，Loomba R.Global epidemiology of NAFLD-related HCC：trends，predictions，risk factors and prevention［J］.Nat Rev Gastroenterol Hepatol，2021，18：223-238.
［10］Shah PA，Patil R，Harrison SA.NAFLD-related hepatocellular carcinoma：the growing challenge［J］.Hepatology，2023，77：323-338.
［11］宾文婷，常加松，吴剑平.四氯化碳加乙醇复合法诱导肝硬化大鼠模型的建立及验证［J］.中国组织工程研究，2018，22：3224-3229.
［12］向贤宏，李家平，陈柳琴，等.大鼠肝硬化模型制备的改良［J］.当代医学，2009，15：729-731.
［13］Xia HM，Wang J，Xie XJ，et al.Green tea polyphenols attenuate hepatic steatosis，and reduce insulin resistance and inflammation in high-fat diet-induced rats［J］.Int J Mol Med，2019，44：1523-1530.
［14］Carbajo-Pescador S，Porras D，García-Mediavilla MV，et al.Beneficial effects of exercise on gutmicrobiotafunctionality and barrier integrity，and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease［J］.Dis Model Mech，2019，12：dmm039206.
［15］陈雯，王静捷，黄宇光.用Walker256大鼠乳腺癌细胞建立大鼠胫骨癌痛模型［J］.协和医学杂志，2011，2：350-356.
［16］江剑平，江方璐，李幼萍.腹水Walker256乳腺癌细胞接种建立SD大鼠胫骨骨癌痛模型［J］.福建师范大学学报（自然科学版），2019，35：50-55.
［17］赵航，郭思敏，马中翔，等.大鼠胃十二指肠动脉逆行给药的研究［J］.介入放射学杂志，2023，32：456-458.
［18］Liu J，Zhang L，Zhao DX，et al.Polymersome-stabilized doxorubicin-lipiodol emulsions for high-efficacy chemoembolization therapy［J］.J Control Release，2022，350：122-131.
［19］Park W，Cho S，Ji J，et al.Development and validation of sorafenib-eluting microspheres to enhance therapeutic efficacy of transcatheter arterial chemoembolization in a rat model of hepatocellular carcinoma［J］.Radiol Imaging Cancer，2021，3：e200006.
［20］Li T，Liu J，Wang Y，et al.Liver fibrosis promotes immunity escape but limits the size of liver tumor in a rat orthotopic transplantation model［J］.Sci Rep，2021，11：22846.
［21］Jain A，Mazer B，Deng YH，et al.Hepatocellular carcinoma：does the background liver with or without cirrhosis matter?［J］.Am J Clin Pathol，2022，157：305-313.
［22］Young S，Sanghvi T，Rubin N，et al.Transarterial chemoembolization of hepatocellular carcinoma：propensity score matching study comparing survival and complications in patients with nonalcoholic steatohepatitis versus other causes cirrhosis［J］.Cardiovasc Intervent Radiol，2020，43：65-75.
［23］Wu SE，Charles HW，Park JS，et al.Obesity conveys poor outcome in patients with hepatocellular carcinoma treated by transarterial chemoembolization［J］.Diagn Interv Imaging，2017，98：37-42.
［24］Wang Q，Zhang F，Lei Y，et al.MicroRNA-322/424 promotes liver fibrosis by regulating angiogenesis through targeting CUL2/HIF-1α pathway［J］.Life Sci，2021，266：118819.
［25］Lei HW，Huang BR，Cai J，et al.CXCR4 antagonist AMD3100 enhances therapeutic efficacy of transcatheter arterial chemoembolization in rats with hepatocellular carcinoma［J］.Kaohsiung J Med Sci，2022，38：781-789.

相似文献/References:

[1]曹海利,孟巍,白彬.肝癌基因治疗研究新进展[J].介入放射学杂志,2008,(05):375.
　CAO Haili,MENG Wei,BAI Bin.New progress in research of gene therapy for hepatocellular carcinoma[J].journal interventional radiology,2008,(10):375.
[2]陆骊工,胡宝山,李勇,等.中晚期原发性肝癌合并症的介入治疗研究[J].介入放射学杂志,2008,(07):514.
　LU Ligong,HU Baoshan,LI Yong,et al.Study of interventional therapy for complications in advanced primary hepatocellular carcinoma[J].journal interventional radiology,2008,(10):514.
[3]杨伟洪,刘鹏程,梁珊瑚,等.多层螺旋CT血管造影在判断肝癌寄生供血中的价值[J].介入放射学杂志,2008,(09):654.
　YANG Weihong,LIU Pengchen g,LIANG Shanhu,et al.Evaluation of MSCTA for parasitic blood supply in hepatic carcinoma[J].journal interventional radiology,2008,(10):654.
[4]张茵,周兵,许秀芳,等.肝动脉化疗栓塞治疗原发性肝癌存活２０年一例[J].介入放射学杂志,2008,(09):684.
　ZHANG Yin,ZHOU Bing,XU Xiufang,et al.Survival more than２０years after transarterial chemical embolization for hepatocellular carcinoma：A case report[J].journal interventional radiology,2008,(10):684.
[5]官泳松,贺庆.肝癌介入治疗中应用p５３的几个要点[J].介入放射学杂志,2008,(11):761.
　GUAN Yongsong,HE Qing.Essentials in clinical application of p５３for tumors intervention－example of liver cancer[J].journal interventional radiology,2008,(10):761.
[6]肖运平,肖恩华.介入治疗在防治肝癌术后复发中的作用及进展[J].介入放射学杂志,2008,(11):831.
　XIAO Yunping,XIAO Enhua.The role and progress of interventional therapy in the prevention and treatment of postoperative hepatocellular carcinoma recurrence[J].journal interventional radiology,2008,(10):831.
[7]史震山,陈自谦,杨熙章,等.原发性大肝癌患者TACE后S－腺苷蛋氨酸的护肝作用[J].介入放射学杂志,2008,(11):790.
　SHI Zhenshan,CHEN Ziqian,YANG Xizhang,et al.The clinical study on the liver－protection of S－adenosy－methionine in large hepatocellular carcinoma patients after TACE[J].journal interventional radiology,2008,(10):790.
[8]王耀普,杨康健,赵思源,等.兔肝癌模型的改良接种及其DSA影像分析[J].介入放射学杂志,2010,(03):214.
　WANG Yaopu,YANG Kangjian,ZHAO Siyuan,et al.The modified inoculation method for the preparation of rabbit VX２hepatic carcinoma model and DSA imagining observation[J].journal interventional radiology,2010,(10):214.
[9]贺洪德,贺晶,罗中华,等.肝动脉化疗栓塞联合门静脉栓塞治疗中晚期肝癌的疗效评价[J].介入放射学杂志,2010,(03):191.
　HE Hongde,HE Jing,LUO Zhonghua,et al.Evaluation of the therapeutic effect of hepatic arterial chemoembolization combined with portal chemoembolization for advanced hepatic carcinomas[J].journal interventional radiology,2010,(10):191.
[10]李广琪,曹玮,李超,等.肝动脉热灌注对兔肝VX２肿瘤及正常肝组织血管渗透性功能的作用[J].介入放射学杂志,2010,(03):217.
　LI Guangqi,CAO Wei,LI Chao,et al.Influence of hepatic artery thermotherapy on the vascular permeability of hepatic tumor tissue and normal liver tissue in VX２tumor－bearing rabbits[J].journal interventional radiology,2010,(10):217.

备注/Memo

备注/Memo:
（收稿日期：2024-03-25）
（本文编辑：茹实）
更新日期/Last Update: 2024-10-17